MPO and acute myeloid leukemia: CD34(+) [11, 15], leukemic stem cell (LSC) phenotype CD34(+)/CD38(−)/CD123(+) [16], APL-like phenotype CD34(−)/HLA-DR(−)/MPO(str+) [12] and clustered type-II phenotype CD34(+)/HLA-DR(+)/CD7(+) [17] have been reported to convey prognostic effects on NPM1mut AML.